Articles By Rob Wright

  1. Pharmaceutical Serialization Is Doomed Unless We Implement A Big-Picture Approach 4/30/2012

    Pharmaceutical serialization could obtain a global standardization by learning from two different models which demonstrate a solution. By Rob Wright

  2. Getting A Biotech Back On The Path Toward Commercialization 3/28/2012

    There has been much debate as to how much it costs to get a new drug from discovery to market — anywhere from Light and Waburton’s 2011 estimate of R&D costs being in the neighborhood of $59.4M to PhRMA’s mind-numbing figure of $1.32B. By Rob Wright

  3. Building A Biotech In China 3/8/2012

    Pharmaceutical and biotech companies are looking to emerging markets as the next frontier for drug development, discovery, and perhaps, the next breakthrough. By Rob Wright, Life Science Leader magazine

  4. Trevena's Maxine Gowen: Next-Generation Leadership 6/9/2011

    In 2007, a group of scientists from Duke University began the process of pursuing VC funding to start a company. By Rob Wright, Life Science Leader magazine

  5. Lessons Learned Help Pfizer Accelerate Biotherapeutic Development

    Six of the seven blockbuster biotherapeutics belonging to Big Pharma have roots to small biotechs (see Table 1). So too does Tim Charlebois, Ph.D., VP of technology and innovation strategy within Pfizer’s biotherapeutics pharmaceutical sciences (BTx Pharm Sci).